An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Chinese human-like robots have attracted attention following their participation in a 100-meter dash event where…
The Onam festival of 2026 is being celebrated throughout the state of Kerala through colorful…
The US government has unveiled an operation called Economic Outcast, which is a new global…
The National Security Guard (NSG) has inaugurated the first-ever Mahila Commando Conversion Course (MCCC) at…
National Conclave on Tribal Languages and Museums was launched in the Mysuru, Karnataka, on August…
As per a recent report released by NITI Aayog, close to 8.7 crore Indians between…